Vanotti Sandra, Caceres Fernando J
Multiple Sclerosis Clinic, INEBA - Neurosciences Institute of Buenos Aires, Argentina.
Mult Scler J Exp Transl Clin. 2017 Sep 25;3(3):2055217317717508. doi: 10.1177/2055217317717508. eCollection 2017 Jul-Sep.
Cognitive and neuropsychiatric disorders in patients with multiple sclerosis have been extensively documented. The focus of this review will be on cognitive and neuropsychiatric disorders in multiple sclerosis patients from Latin America, in the context of international literature. Multicentre studies carried out in Latin America have shown that 43% of the patients have cognitive impairment and 34.5% in early stages of the disease, 29% depression and 20.9% neuropsychiatric disorders. The profile of cognitive impairment corresponds to alterations in visual and verbal memory, in attention, in information processing speed and in verbal fluency. The neuropsychiatric profile showed disorders in anxiety, depression, apathy and irritability domains. In the region, there exist validations of the multiple sclerosis neuropsychological screening questionnaire (MSNQ), the brief repeatable battery of neuropsychological tests (BRB-N) and the brief international cognitive assessment for multiple sclerosis (BICAMS), as well as of the paced auditory serial addition test (PASAT) and the symbol digit modalities test (SDMT). A study showed that 53% of the patients who met the NEDA3 condition had cognitive impairment. This finding highlights the need for taking cognitive assessment into account when determining therapeutic efficacy.
多发性硬化症患者的认知和神经精神障碍已有大量文献记载。本综述的重点将是在国际文献背景下,拉丁美洲多发性硬化症患者的认知和神经精神障碍。在拉丁美洲进行的多中心研究表明,43%的患者存在认知障碍,疾病早期阶段这一比例为34.5%,29%的患者有抑郁症,20.9%的患者有神经精神障碍。认知障碍的特征表现为视觉和言语记忆、注意力、信息处理速度和言语流畅性方面的改变。神经精神特征表现为焦虑、抑郁、冷漠和易怒领域的障碍。在该地区,多发性硬化症神经心理学筛查问卷(MSNQ)、简短重复神经心理测验组(BRB-N)和多发性硬化症简短国际认知评估(BICAMS)以及听觉连续加法测验(PASAT)和符号数字模式测验(SDMT)均已得到验证。一项研究表明,符合NEDA3条件的患者中有53%存在认知障碍。这一发现凸显了在确定治疗效果时考虑认知评估的必要性。